Fabry  ||| S:0 E:6 ||| JJ
disease ||| S:6 E:13 ||| NN
:  ||| S:13 E:15 ||| :
perspectives  ||| S:15 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
urinary  ||| S:31 E:39 ||| FW
proteomics  ||| S:39 E:50 ||| FW
Fabry  ||| S:50 E:56 ||| FW
disease  ||| S:56 E:64 ||| FW
( ||| S:64 E:65 ||| -LRB-
FD ||| S:65 E:67 ||| NNP
)  ||| S:67 E:69 ||| -RRB-
is  ||| S:69 E:72 ||| VBZ
an  ||| S:72 E:75 ||| DT
X-linked  ||| S:75 E:84 ||| JJ
lysosomal  ||| S:84 E:94 ||| JJ
storage  ||| S:94 E:102 ||| NN
disorder  ||| S:102 E:111 ||| NN
caused  ||| S:111 E:118 ||| VBN
by  ||| S:118 E:121 ||| IN
mutations  ||| S:121 E:131 ||| NNS
in  ||| S:131 E:134 ||| IN
the  ||| S:134 E:138 ||| DT
gene  ||| S:138 E:143 ||| NN
encoding  ||| S:143 E:152 ||| VBD
the  ||| S:152 E:156 ||| DT
lysosomal  ||| S:156 E:166 ||| JJ
enzyme  ||| S:166 E:173 ||| JJ
a-galactosidase  ||| S:173 E:189 ||| JJ
A  ||| S:189 E:191 ||| NNP
( ||| S:191 E:192 ||| -LRB-
a-GalA ||| S:192 E:198 ||| NNP
) ||| S:198 E:199 ||| -RRB-
.  ||| S:199 E:201 ||| .
The  ||| S:201 E:205 ||| DT
resulting  ||| S:205 E:215 ||| JJ
deficiency  ||| S:215 E:226 ||| NN
in  ||| S:226 E:229 ||| IN
a-GalA  ||| S:229 E:236 ||| JJ
activity  ||| S:236 E:245 ||| NN
leads  ||| S:245 E:251 ||| VBZ
to  ||| S:251 E:254 ||| TO
intra-lysosomal  ||| S:254 E:270 ||| JJ
accumulation  ||| S:270 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
neutral  ||| S:286 E:294 ||| JJ
glycosphingolipids ||| S:294 E:312 ||| NN
,  ||| S:312 E:314 ||| ,
mainly  ||| S:314 E:321 ||| RB
globotriaosylceramide  ||| S:321 E:343 ||| JJ
( ||| S:343 E:344 ||| -LRB-
Gb3 ||| S:344 E:347 ||| NNP
) ||| S:347 E:348 ||| -RRB-
,  ||| S:348 E:350 ||| ,
in  ||| S:350 E:353 ||| IN
various  ||| S:353 E:361 ||| JJ
organ  ||| S:361 E:367 ||| NN
systems ||| S:367 E:374 ||| NNS
.  ||| S:374 E:376 ||| .
As  ||| S:376 E:379 ||| IN
a  ||| S:379 E:381 ||| DT
consequence ||| S:381 E:392 ||| NN
,  ||| S:392 E:394 ||| ,
a  ||| S:394 E:396 ||| DT
multisystem  ||| S:396 E:408 ||| JJ
disorder  ||| S:408 E:417 ||| NN
develops ||| S:417 E:425 ||| VBZ
,  ||| S:425 E:427 ||| ,
culminating  ||| S:427 E:439 ||| VBG
in  ||| S:439 E:442 ||| IN
strokes  ||| S:442 E:450 ||| NNS
and  ||| S:450 E:454 ||| CC
progressive  ||| S:454 E:466 ||| JJ
renal  ||| S:466 E:472 ||| NN
and  ||| S:472 E:476 ||| CC
cardiac  ||| S:476 E:484 ||| JJ
dysfunction ||| S:484 E:495 ||| NN
.  ||| S:495 E:497 ||| .
Enzyme  ||| S:497 E:504 ||| JJ
replacement  ||| S:504 E:516 ||| NN
therapy  ||| S:516 E:524 ||| NN
( ||| S:524 E:525 ||| -LRB-
ERT ||| S:525 E:528 ||| NNP
)  ||| S:528 E:530 ||| -RRB-
offers  ||| S:530 E:537 ||| VBZ
a  ||| S:537 E:539 ||| DT
specific  ||| S:539 E:548 ||| JJ
treatment  ||| S:548 E:558 ||| NN
for  ||| S:558 E:562 ||| IN
patients  ||| S:562 E:571 ||| NNS
affected  ||| S:571 E:580 ||| VBN
by  ||| S:580 E:583 ||| IN
FD ||| S:583 E:585 ||| NNP
,  ||| S:585 E:587 ||| ,
though  ||| S:587 E:594 ||| IN
monitoring  ||| S:594 E:605 ||| VBG
treatment  ||| S:605 E:615 ||| NN
is  ||| S:615 E:618 ||| VBZ
hampered  ||| S:618 E:627 ||| VBN
by  ||| S:627 E:630 ||| IN
a  ||| S:630 E:632 ||| DT
lack  ||| S:632 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
surrogate  ||| S:640 E:650 ||| JJ
markers  ||| S:650 E:658 ||| NN
of  ||| S:658 E:661 ||| IN
response ||| S:661 E:669 ||| NN
.  ||| S:669 E:671 ||| .
Furthermore ||| S:671 E:682 ||| RB
,  ||| S:682 E:684 ||| ,
even  ||| S:684 E:689 ||| RB
if  ||| S:689 E:692 ||| IN
signs  ||| S:692 E:698 ||| NNS
and  ||| S:698 E:702 ||| CC
symptoms  ||| S:702 E:711 ||| NNS
of  ||| S:711 E:714 ||| IN
the  ||| S:714 E:718 ||| DT
disease  ||| S:718 E:726 ||| NN
become  ||| S:726 E:733 ||| VBN
manifest  ||| S:733 E:742 ||| VBN
in  ||| S:742 E:745 ||| IN
childhood ||| S:745 E:754 ||| NN
,  ||| S:754 E:756 ||| ,
its  ||| S:756 E:760 ||| PRP$
diagnosis  ||| S:760 E:770 ||| NN
is  ||| S:770 E:773 ||| VBZ
often  ||| S:773 E:779 ||| RB
delayed ||| S:779 E:786 ||| VBN
.  ||| S:786 E:788 ||| .
Biomarkers  ||| S:788 E:799 ||| NNS
that  ||| S:799 E:804 ||| WDT
predict  ||| S:804 E:812 ||| VBP
disease  ||| S:812 E:820 ||| NN
progression  ||| S:820 E:832 ||| NNS
and  ||| S:832 E:836 ||| CC
respond  ||| S:836 E:844 ||| VB
relatively  ||| S:844 E:855 ||| RB
quickly  ||| S:855 E:863 ||| RB
to  ||| S:863 E:866 ||| TO
effective  ||| S:866 E:876 ||| JJ
therapy  ||| S:876 E:884 ||| NN
may  ||| S:884 E:888 ||| MD
be  ||| S:888 E:891 ||| VB
useful  ||| S:891 E:898 ||| JJ
to  ||| S:898 E:901 ||| TO
follow  ||| S:901 E:908 ||| VB
individual  ||| S:908 E:919 ||| JJ
patients  ||| S:919 E:928 ||| NNS
or  ||| S:928 E:931 ||| CC
groups  ||| S:931 E:938 ||| NNS
of  ||| S:938 E:941 ||| IN
patients ||| S:941 E:949 ||| NNS
.  ||| S:949 E:951 ||| .
Here  ||| S:951 E:956 ||| RB
we  ||| S:956 E:959 ||| PRP
report  ||| S:959 E:966 ||| VBP
the  ||| S:966 E:970 ||| DT
use  ||| S:970 E:974 ||| NN
of  ||| S:974 E:977 ||| IN
2  ||| S:977 E:979 ||| CD
different  ||| S:979 E:989 ||| JJ
mass  ||| S:989 E:994 ||| NN
spectrometry-based  ||| S:994 E:1013 ||| JJ
proteomic  ||| S:1013 E:1023 ||| JJ
techniques  ||| S:1023 E:1034 ||| NNS
to  ||| S:1034 E:1037 ||| TO
identify  ||| S:1037 E:1046 ||| VB
disease-associated  ||| S:1046 E:1065 ||| JJ
compositional  ||| S:1065 E:1079 ||| JJ
changes  ||| S:1079 E:1087 ||| NNS
that  ||| S:1087 E:1092 ||| WDT
can  ||| S:1092 E:1096 ||| MD
be  ||| S:1096 E:1099 ||| VB
used  ||| S:1099 E:1104 ||| VBN
as  ||| S:1104 E:1107 ||| IN
early  ||| S:1107 E:1113 ||| JJ
biomarkers  ||| S:1113 E:1124 ||| NN
of  ||| S:1124 E:1127 ||| IN
the  ||| S:1127 E:1131 ||| DT
pathology ||| S:1131 E:1140 ||| NN
,  ||| S:1140 E:1142 ||| ,
as  ||| S:1142 E:1145 ||| RB
well  ||| S:1145 E:1150 ||| RB
as  ||| S:1150 E:1153 ||| RB
for  ||| S:1153 E:1157 ||| IN
monitoring  ||| S:1157 E:1168 ||| VBG
the  ||| S:1168 E:1172 ||| DT
effectiveness  ||| S:1172 E:1186 ||| NN
of  ||| S:1186 E:1189 ||| IN
ERT ||| S:1189 E:1192 ||| NNP
.  ||| S:1192 E:1194 ||| .
To  ||| S:1194 E:1197 ||| TO
this  ||| S:1197 E:1202 ||| DT
purpose ||| S:1202 E:1209 ||| NN
,  ||| S:1209 E:1211 ||| ,
we  ||| S:1211 E:1214 ||| PRP
compared  ||| S:1214 E:1223 ||| VBD
the  ||| S:1223 E:1227 ||| DT
renal  ||| S:1227 E:1233 ||| JJ
Fabry  ||| S:1233 E:1239 ||| JJ
urinary  ||| S:1239 E:1247 ||| JJ
proteome  ||| S:1247 E:1256 ||| NN
with  ||| S:1256 E:1261 ||| IN
normal  ||| S:1261 E:1268 ||| JJ
( ||| S:1268 E:1269 ||| -LRB-
control ||| S:1269 E:1276 ||| NN
)  ||| S:1276 E:1278 ||| -RRB-
urine  ||| S:1278 E:1284 ||| VBP
using ||| S:1284 E:1289 ||| VBG
,  ||| S:1289 E:1291 ||| ,
respectively ||| S:1291 E:1303 ||| RB
,  ||| S:1303 E:1305 ||| ,
2-dimensional  ||| S:1305 E:1319 ||| CD
gel  ||| S:1319 E:1323 ||| CD
electrophoresis  ||| S:1323 E:1339 ||| NNS
and  ||| S:1339 E:1343 ||| CC
label-free  ||| S:1343 E:1354 ||| JJ
quantification ||| S:1354 E:1368 ||| NN
.  ||| S:1368 E:1370 ||| .
Our  ||| S:1370 E:1374 ||| PRP$
preliminary  ||| S:1374 E:1386 ||| JJ
results  ||| S:1386 E:1394 ||| NNS
show  ||| S:1394 E:1399 ||| VBP
that  ||| S:1399 E:1404 ||| IN
the  ||| S:1404 E:1408 ||| DT
urinary  ||| S:1408 E:1416 ||| JJ
protein  ||| S:1416 E:1424 ||| NN
pattern  ||| S:1424 E:1432 ||| NN
of  ||| S:1432 E:1435 ||| IN
affected  ||| S:1435 E:1444 ||| JJ
patients  ||| S:1444 E:1453 ||| NNS
can  ||| S:1453 E:1457 ||| MD
be  ||| S:1457 E:1460 ||| VB
easily  ||| S:1460 E:1467 ||| RB
distinguished  ||| S:1467 E:1481 ||| VBN
from  ||| S:1481 E:1486 ||| IN
that  ||| S:1486 E:1491 ||| DT
of  ||| S:1491 E:1494 ||| IN
healthy  ||| S:1494 E:1502 ||| JJ
subjects  ||| S:1502 E:1511 ||| NNS
both  ||| S:1511 E:1516 ||| DT
qualitatively  ||| S:1516 E:1530 ||| NN
and  ||| S:1530 E:1534 ||| CC
quantitatively ||| S:1534 E:1548 ||| NN
,  ||| S:1548 E:1550 ||| ,
thus  ||| S:1550 E:1555 ||| RB
encouraging  ||| S:1555 E:1567 ||| VBG
further  ||| S:1567 E:1575 ||| JJ
studies  ||| S:1575 E:1583 ||| NNS
in  ||| S:1583 E:1586 ||| IN
the  ||| S:1586 E:1590 ||| DT
search  ||| S:1590 E:1597 ||| NN
for  ||| S:1597 E:1601 ||| IN
FD-specific  ||| S:1601 E:1613 ||| JJ
biomarkers  ||| S:1613 E:1624 ||| NNS
using  ||| S:1624 E:1630 ||| VBG
this  ||| S:1630 E:1635 ||| DT
proteomic  ||| S:1635 E:1645 ||| JJ
approach ||| S:1645 E:1653 ||| NN
.  ||| S:1653 E:1655 ||| .
